NCT03470103View on ClinicalTrials.gov

A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America

CompletedOBSERVATIONAL
Enrollment

643

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

September 21, 2020

Study Completion Date

January 15, 2021

Conditions
Macular Degeneration
Interventions
DRUG

Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

Use of intravitreal aflibercept in routine clinical practice in Latin America

Trial Locations (4)

Unknown

Many locations, Multiple Locations

Many locations, Multiple Locations

Many locations, Multiple Locations

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY